10x Genomics (TXG) Change in Account Payables (2018 - 2026)

10x Genomics (TXG) has 9 years of Change in Account Payables data on file, last reported at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 287.75% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (up 149.63% YoY), and the FY2025 full-year result was -$2.1 million, up 36.61% from the prior year.
• Change in Account Payables climbed to $4.8 million in Q1 2026, from -$5.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $7.4 million in Q2 2022 to a low of -$13.4 million in Q4 2024.
• A 5-year average of -$50411.8 and a median of -$196000.0 in 2025 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 729.22% in 2022 and plunged 1331.25% in 2023, its largest moves.
• Tracing TXG's Change in Account Payables over 5 years: stood at -$224000.0 in 2022, then sank by 1331.25% to -$3.2 million in 2023, then plunged by 317.9% to -$13.4 million in 2024, then surged by 59.56% to -$5.4 million in 2025, then jumped by 188.26% to $4.8 million in 2026.
• Business Quant data shows TXG's Change in Account Payables at $4.8 million in Q1 2026, -$5.4 million in Q4 2025, and -$196000.0 in Q3 2025.